Claudin18.2 expression in gallbladder cancer correlates with immune activation and a favourable prognosis
The correlations between the expression of CLDN18.2 and clinicopathological characteristics and prognosis suggest that early-stage patients could benefit more from future anti-CLDN18.2 treatment and that CLDN18.2 may function as a pivotal regulatory molecule in patients with GBC. The underlying mechanism may be related to immune activation caused by high CLDN18.2 expression.
Authors
- Lin Yuan
- Shujuan Ni (ORCID: https://orcid.org/0000-0002-8030-0294)
- Xu Cai (ORCID: https://orcid.org/0000-0002-1621-2257)
- Hui Sun (ORCID: https://orcid.org/0000-0002-7145-6991)
- Dan Huang (ORCID: https://orcid.org/0000-0003-4221-574X)
- Midie Xu
- Weiqi Sheng
- Hui Dong (ORCID: https://orcid.org/0000-0002-2244-2040)
- Xin Wang (ORCID: https://orcid.org/0000-0001-8051-1481)
- Cong Tan (ORCID: https://orcid.org/0000-0002-7985-6682)
- Wenhua Jiang
Institutions
- Shanghai Medical College of Fudan University (CN)
- Second Military Medical University (CN)
- Shanghai Jiao Tong University (CN)
- Fudan University Shanghai Cancer Center (CN)
- Shanghai First People's Hospital (CN)
- Eastern Hepatobiliary Surgery Hospital (CN)
Publication Details
- Journal
- Journal of Clinical Pathology
- Published
- 2025-02-13
- DOI
- https://doi.org/10.1136/jcp-2024-209914
- Citations
- 2
- Primary Topic
- Barrier Structure and Function Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.68
Funders
- Shanghai Municipal Health Commission
- National Natural Science Foundation of China